These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16278769)

  • 1. Ziprasidone mesylate (Geodon for injection): the first injectable atypical antipsychotic medication.
    Sheehan V
    Proc (Bayl Univ Med Cent); 2003 Oct; 16(4):497-501. PubMed ID: 16278769
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations.
    Thombre AG; Shah JC; Sagawa K; Caldwell WB
    Int J Pharm; 2012 May; 428(1-2):8-17. PubMed ID: 22349051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best clinical practice with ziprasidone IM: update after 2 years of experience.
    Zimbroff DL; Allen MH; Battaglia J; Citrome L; Fishkind A; Francis A; Herr DL; Hughes D; Martel M; Preval H; Ross R
    CNS Spectr; 2005 Sep; 10(9):1-15. PubMed ID: 16247923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziprasidone: a novel psychotropic with unique properties.
    Ballas C; Yang C; O'Reardon J; Ballas P; Baldassano C
    Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profound hypothermia secondary to normal ziprasidone use.
    Gibbons GM; Wein DA; Paula R
    Am J Emerg Med; 2008 Jul; 26(6):737.e1-2. PubMed ID: 18606348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.
    Stimmel GL; Gutierrez MA; Lee V
    Clin Ther; 2002 Jan; 24(1):21-37. PubMed ID: 11833834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziprasidone for schizophrenia and severe mental illness.
    Bagnall A; Lewis RA; Leitner ML
    Cochrane Database Syst Rev; 2000; (4):CD001945. PubMed ID: 11034737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Scott LJ
    CNS Drugs; 2006; 20(12):1027-52. PubMed ID: 17140281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the reconstitution of intramuscular ziprasidone (Geodon) into solution.
    Ewing JD; Rund DA; Votolato NA
    Ann Emerg Med; 2004 Mar; 43(3):419-20. PubMed ID: 15252940
    [No Abstract]   [Full Text] [Related]  

  • 10. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder.
    Zhu B; Kulkarni PM; Stensland MD; Ascher-Svanum H
    Curr Med Res Opin; 2007 Nov; 23(11):2805-14. PubMed ID: 17910804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone for schizophrenia and severe mental illness.
    Bagnall A; Lewis RA; Leitner ML; Kleijnen J
    Cochrane Database Syst Rev; 2000; (2):CD001945. PubMed ID: 10796670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric uptake of a newly available antipsychotic medication.
    Penfold RB; Kelleher KJ; Wang W; Strange B; Pajer K
    Pediatrics; 2010 Mar; 125(3):475-82. PubMed ID: 20142282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone metabolism, aldehyde oxidase, and clinical implications.
    Beedham C; Miceli JJ; Obach RS
    J Clin Psychopharmacol; 2003 Jun; 23(3):229-32. PubMed ID: 12826984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management.
    Cobaugh DJ; Erdman AR; Booze LL; Scharman EJ; Christianson G; Manoguerra AS; Caravati EM; Chyka PA; Woolf AD; Nelson LS; Troutman WG
    Clin Toxicol (Phila); 2007 Dec; 45(8):918-42. PubMed ID: 18163235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.
    Greenberg WM; Citrome L
    CNS Drug Rev; 2007; 13(2):137-77. PubMed ID: 17627670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ziprasidone (Geodon) for schizophrenia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
    [No Abstract]   [Full Text] [Related]  

  • 18. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.